03 Profile
Hansard to 9 November 2026 · 31,243 contributions indexed · 1,439 MPs & peers
All voices01 Voice · Clinician · Diabetes
Juan Carlos Bazo-Alvarez
Dr, from the department of epidemiology and health at University College London (UCL), one of the researchers on the study
press citation on 1 topic since 15 Oct 2026 · last quoted 15 Oct 2026
02 Quoted on · 1 of 29 topics
Juan Carlos Bazo-Alvarez: key facts
- Kind of voice
- Clinician
- Role
- Dr, from the department of epidemiology and health at University College London (UCL), one of the researchers on the study
- Quoted on
- Diabetes
- Tracked press citations
- 1
- Most recently quoted
- 15 Oct 2026
04 The signal · where Juan Carlos Bazo-Alvarez sits on diabetes
Ranked 45= of 100 voices quoted in the press on diabetes, level with 55 others on 1 citation.
Ranked on press citations on this topic only, not across all topics. Joint positions share a rank.
- 1
Douglas TwenefourClinicianHead of Clinical, Diabetes UK11 - 2
Helen KnightRegulatorDirector of Medicines Evaluation, National Institute for Health and Care Excellence (NICE)9 - 3
Parth NarendranAcademicProfessor of Diabetes Medicine; Honorary Consultant Physician (leads the Type 1 Diabetes clinical service at the Queen Elizabeth Hospital Birmingham), University of Birmingham7 - 45=Andrea SanabriaClinicianDr, interim director of Public Health1
- 45=Robert GehoSector leaderCo-founder and CEO of Diasome1
- 45=Juan Carlos Bazo-AlvarezClinicianDr, from the department of epidemiology and health at University College London (UCL), one of the researchers on the study1
- 45=Zoe KolokotroniClinician1
- 45=Damola AjeAcademicMassachusetts-based endocrinologist1
Showing the leaders and the ranks around 45=, of 100 voices · See every voice on the topic →
05 On the record · press
What Juan Carlos Bazo-Alvarez has said
- nursingtimes.net1
Where Juan Carlos Bazo-Alvarez has been quoted
- 01Antipsychotic diabetes risk ‘peaks in first 90 days’nursingtimes.net · 15 Oct 2026
Verbatim
“"Our study shows that the first 90 days after starting treatment are a key period when changes linked to diabetes and weight gain can begin."”
Related media coverage
Recent UK press coverage of their topics, not necessarily citing them directly.
- First UK patient treated with NICE approved TeplizumabUniversity of Birmingham
- Branding update for insulin pensDiabetes Research & Wellness Foundation
- DRWF Events: Register now for Diabetes: A Whole Life BlueprintDiabetes Research & Wellness Foundation
Doctors, nurses, allied health professionals and other registered clinicians quoted in a clinical capacity. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 22 Oct 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.